Valuation: Natera, Inc.

Market Cap 38.66B 33.91B 31.41B 28.9B 54.66B 3,700B 55.72B 374B 147B 1,817B 145B 142B 6,276B P/E 2026 *
-162x
P/E 2027 * -1,135x
Enterprise Value 37.64B 33.01B 30.57B 28.13B 53.21B 3,602B 54.25B 364B 143B 1,769B 141B 138B 6,109B EV / Sales 2026 *
13.5x
EV / Sales 2027 * 11.2x
Free-Float
97.02%
Yield 2026 *
-
Yield 2027 * -
1 day-0.35%
1 week-3.84%
Current month+0.53%
1 month+25.77%
3 months+35.16%
6 months+14.71%
Current year+19.12%
1 week 261.63
Extreme 261.63
287.64
1 month 209.57
Extreme 209.57
288.04
Current year 181
Extreme 181
288.04
1 year 131.81
Extreme 131.8106
288.04
3 years 36.9
Extreme 36.9
288.04
5 years 26.1
Extreme 26.1
288.04
10 years 7.35
Extreme 7.35
288.04
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

Founder

-1,000 0.0007%
06-30Sell

General Counsel

-16,800 0.0117%
06-30Sell

Executive/Senior Manager

-3,000 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+1.09%-3.84%+72.52%+437.29% 38.66B
-0.05%-2.71%+10.76%+30.67% 22.7B
-1.46%-1.51%-23.11%-39.58% 7.3B
-3.49%-8.14%+11.87%+106.96% 5.16B
+1.91%+4.82%+17.90%+44.90% 2.97B
-2.73%-7.32%-22.50%+818.71% 1.95B
-1.17%0.00%+33.47%-19.89% 1.84B
0.00%-6.93%+96.52%-18.81% 1.84B
+4.87%+3.19%+25.58%+4.06% 1.75B
+4.87%+8.21%-8.86%-65.07% 1.68B
Average +0.24%+0.77%+21.41%+129.92% 8.58B
Weighted average by Cap. -0.33%-2.31%+37.49%+226.23%

Financials

2026 *2027 *
Net sales 2.8B 2.45B 2.27B 2.09B 3.96B 268B 4.03B 27.09B 10.62B 132B 10.51B 10.28B 454B 3.33B 2.92B 2.7B 2.49B 4.7B 318B 4.8B 32.21B 12.63B 156B 12.49B 12.22B 540B
Net income -224M -197M -182M -168M -317M -21.45B -323M -2.17B -851M -10.53B -842M -823M -36.38B -28.48M -24.98M -23.13M -21.28M -40.26M -2.73B -41.04M -276M -108M -1.34B -107M -105M -4.62B
Net Debt -1.02B -898M -832M -765M -1.45B -98B -1.48B -9.91B -3.89B -48.13B -3.84B -3.76B -166B -1.3B -1.14B -1.06B -974M -1.84B -125B -1.88B -12.62B -4.95B -61.25B -4.89B -4.79B -212B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-07-13 US$272.89 +1.09% 1,527,679
26-07-10 US$269.95 -4.22% 969,803
26-07-09 US$281.85 +2.72% 1,958,307
26-07-08 US$274.39 -2.45% 1,398,594
26-07-07 US$281.27 -0.89% 1,759,681
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
269.95USD
Average target price
273.38USD
Spread / Average Target
+1.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock